经导管主动脉瓣植入术术后抗栓治疗的研究进展  

Antithrombotic Therapy After Transcatheter Aortic Valve Implantation

作　　者：段振娅 吴永健[1] DUAN Zhenya;WU Yongjian(Department of Cardiology,Fuwai Hospital,National Center for Cardiovascular Disease,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100037,China)

机构地区：[1]北京协和医学院国家心血管病中心中国医学科学院阜外医院心内科,北京100037

出　　处：《心血管病学进展》2022年第7期577-581,共5页Advances in Cardiovascular Diseases

基　　金：国家重点研发计划资助(2020YFC2008100)。

摘　　要：经导管主动脉瓣植入术现已成为治疗症状性重度主动脉瓣狭窄的一项重要的治疗方法。血栓栓塞和出血事件为经导管主动脉瓣植入术后常见并发症,如何制定出平衡好二者风险的抗栓策略具有重要的临床意义。目前研究主要聚焦于抗血小板治疗、冠状动脉介入术后抗栓治疗、合并心房颤动时的抗凝治疗、生物瓣膜血栓抗凝治疗以及预防血栓器械干预治疗等方面。现就近年研究进展及共识和指南更新进行介绍。Transcatheter aortic valve implantation(TAVI)has now become an important treatment for symptomatic severe aortic stenosis.Thromboembolism and bleeding events are common complications after TAVI.How to develop an antithrombotic strategy that balances the risks of the two has important clinical significance.The current research mainly focuses on antiplatelet therapy,antithrombotic therapy after coronary intervention,anticoagulation therapy when combined with atrial fibrillation,anticoagulation therapy for biological valve thrombosis,and interventional therapy for thrombus prevention devices.This article introduces recent research progresses,consensus and guideline updates.

关 键 词：经导管主动脉瓣植入术 抗栓治疗 血栓栓塞 出血 

分 类 号：R654.2[医药卫生—外科学]